These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38117536)

  • 1. Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study.
    Luo W; Shi Z; Kong L; Wang X; Zhou H
    Eur J Neurol; 2024 Mar; 31(3):e16178. PubMed ID: 38117536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
    Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
    Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.
    Palace J; Lin DY; Zeng D; Majed M; Elsone L; Hamid S; Messina S; Misu T; Sagen J; Whittam D; Takai Y; Leite MI; Weinshenker B; Cabre P; Jacob A; Nakashima I; Fujihara K; Pittock SJ
    Brain; 2019 May; 142(5):1310-1323. PubMed ID: 30938427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders.
    Amaral JM; Talim N; Kleinpaul R; Lana-Peixoto MA;
    Mult Scler Relat Disord; 2020 Jun; 41():102045. PubMed ID: 32179485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder.
    Hu Y; Sun Q; Yi F; Yao L; Tian Y; Tang H; Luo M; Xie N; Wang Z; Liao X; Zhou L; Xu H; Zhou Y
    Front Immunol; 2022; 13():1056944. PubMed ID: 36569880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder.
    Liu YH; Guo YC; Lin LY; Tsai CP; Fuh JL; Wang YF; Chen SP; Wu HM; Yu KW; Lin KP; Wang SJ; Liao YC; Lee YC
    J Formos Med Assoc; 2022 Sep; 121(9):1647-1656. PubMed ID: 34802834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies.
    Kim SH; Jang H; Park NY; Kim Y; Kim SY; Lee MY; Hyun JW; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33622675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
    Ayzenberg I; Schöllhammer J; Hoepner R; Hellwig K; Ringelstein M; Aktas O; Kümpfel T; Krumbholz M; Trebst C; Paul F; Pache F; Obermann M; Zeltner L; Schwab M; Berthele A; Jarius S; Kleiter I;
    J Neurol; 2016 Mar; 263(3):575-82. PubMed ID: 26810718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.
    Huang W; Tan H; Xia J; Li W; Li X; ZhangBao J; Chang X; Wang L; Wang M; Zhao C; Lu J; Lu C; Dong Q; Zhou L; Quan C;
    Mult Scler Relat Disord; 2022 Oct; 66():104023. PubMed ID: 35843144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder.
    Seok JM; Cho EB; Lee HL; Cho HJ; Min JH; Lee KH; Kim BJ
    J Neurol Sci; 2016 Sep; 368():209-13. PubMed ID: 27538635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
    Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
    Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
    Jarius S; Ruprecht K; Wildemann B; Kuempfel T; Ringelstein M; Geis C; Kleiter I; Kleinschnitz C; Berthele A; Brettschneider J; Hellwig K; Hemmer B; Linker RA; Lauda F; Mayer CA; Tumani H; Melms A; Trebst C; Stangel M; Marziniak M; Hoffmann F; Schippling S; Faiss JH; Neuhaus O; Ettrich B; Zentner C; Guthke K; Hofstadt-van Oy U; Reuss R; Pellkofer H; Ziemann U; Kern P; Wandinger KP; Bergh FT; Boettcher T; Langel S; Liebetrau M; Rommer PS; Niehaus S; Münch C; Winkelmann A; Zettl U UK; Metz I; Veauthier C; Sieb JP; Wilke C; Hartung HP; Aktas O; Paul F
    J Neuroinflammation; 2012 Jan; 9():14. PubMed ID: 22260418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment.
    Tackley G; O'Brien F; Rocha J; Woodhall M; Waters P; Chandratre S; Halfpenny C; Hemingway C; Wassmer E; Wasiewski W; Leite MI; Palace J
    Mult Scler Relat Disord; 2016 May; 7():21-5. PubMed ID: 27237752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very late onset neuromyelitis optica spectrum disorders.
    Nakahara K; Nakane S; Nagaishi A; Narita T; Matsuo H; Ando Y
    Eur J Neurol; 2021 Aug; 28(8):2574-2581. PubMed ID: 33960076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.